IPCA Laboratories

IPCA Laboratories

1,509.00
-31.80
(-2.06%)
ann
There are new updates from the company1 day ago
Viewcross
right
Market Cap
39,090.70 Cr
EPS
29.08
PE Ratio
45.81
Dividend Yield
0.26 %
Industry
Healthcare
52 Week High
1,755.90
52 Week Low
1,168.20
PB Ratio
5.63
Debt to Equity
0.21
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from15 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+73.33 %
+73.33 %
Hold
Hold+20.00 %
+20.00 %
Sell
Sell+6.67 %
+6.67 %
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,699.00
#1 4,05,967.50
35.44
#1 54,729.00
12.06
#1 10,980
-18.99
54.94
6,616.50
1,75,700.40
80.22
9,712.00
0.89
2,191
23.05
42.61
1,532.50
1,20,178.80
23.35
28,409.50
7.12
5,291
9.88
63.13
3,603.80
1,19,129.40
62.12
11,539.40
11.59
1,911
10.91
71.36
2,603.40
1,06,876.10
61.51
12,744.20
19.57
2,007
-10.91
60.17
1,277.90
1,05,615.00
#1 18.58
33,741.20
16.73
5,725
1.26
51.48
976.40
97,730.50
21.02
23,511.00
13.82
4,615
-0.19
53.23
1,951.00
88,662.90
27.33
22,909.50
#1 19.94
3,306
#1 112.49
51.88
33,780.00
73,480.10
52.02
6,684.70
10.80
1,414
27.83
50.65
1,122.80
64,707.10
18.71
31,378.10
17.55
3,366
-0.50
45.80
Forecast
Actual
Growth Rate
Revenue Growth
22.92 %
Net Income Growth
7.58 %
Cash Flow Change
39.87 %
ROE
-17.67 %
ROCE
-3.19 %
EBITDA Margin (Avg.)
11.80 %

Quarterly Financial Results

Quarterly Financials
Jun 2018
Sept 2018
Dec 2018
Mar 2019
Jun 2019
Sept 2019
Dec 2019
Mar 2020
Jun 2020
Sept 2020
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Revenue
890
1,027
1,020
895
1,099
1,299
1,231
1,088
1,547
1,377
1,425
1,135
1,587
1,563
1,443
1,304
1,608
1,637
1,577
1,548
1,630
2,073
2,144
2,052
2,113
2,381
2,266
2,273
Expenses
757
838
772
716
881
1,019
942
908
947
1,003
1,045
886
1,152
1,184
1,123
1,070
1,317
1,341
1,330
1,331
1,278
1,713
1,722
1,848
1,700
1,913
1,782
2,023
EBITDA
133
188
247
179
218
279
289
180
599
374
380
249
435
378
320
234
291
296
247
217
353
360
422
204
413
468
483
250
Operating Profit %
14 %
17 %
23 %
19 %
18 %
21 %
22 %
15 %
38 %
26 %
26 %
21 %
26 %
23 %
22 %
17 %
17 %
16 %
14 %
12 %
19 %
16 %
16 %
9 %
19 %
19 %
21 %
10 %
Depreciation
47
45
46
45
46
50
51
64
51
52
54
53
56
57
59
61
62
64
67
70
69
90
100
98
99
100
99
100
Interest
5
2
5
6
5
4
4
4
3
2
2
2
2
1
1
3
7
9
11
19
31
44
33
29
24
23
17
22
Profit Before Tax
82
141
197
128
167
225
234
112
546
319
324
195
377
320
260
170
223
223
169
129
252
225
289
77
290
345
368
128
Tax
13
22
37
32
37
32
37
29
100
53
57
33
71
68
62
38
78
77
60
51
88
89
68
75
91
99
92
64
Net Profit
69
119
159
96
129
194
198
83
446
267
268
161
307
252
198
132
145
146
110
78
164
137
221
1
199
246
276
64
EPS in ₹
5.43
9.38
12.59
7.60
10.24
15.32
15.63
6.57
35.27
21.11
21.09
12.71
24.18
19.73
7.76
5.13
5.64
5.67
4.25
3.02
6.42
5.72
7.09
2.35
7.58
9.05
9.78
2.67

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total Assets
3,812
3,892
3,960
4,117
4,551
5,260
6,068
7,624
8,626
11,101
11,761
Fixed Assets
1,800
2,014
1,983
1,953
1,940
2,059
2,072
2,402
2,751
4,553
4,267
Current Assets
1,614
1,622
1,742
1,946
2,378
2,856
3,437
4,447
5,189
5,536
5,967
Capital Work in Progress
267
129
95
73
66
133
235
306
140
343
622
Investments
0
26
136
87
120
310
505
989
626
862
980
Other Assets
1,745
1,723
1,746
2,005
2,424
2,758
3,256
3,926
5,109
5,343
5,893
Total Liabilities
3,812
3,892
3,960
4,117
4,551
5,260
6,068
7,624
8,626
11,101
11,761
Current Liabilities
904
970
956
1,008
1,098
1,326
1,161
1,466
1,806
2,356
2,386
Non Current Liabilities
700
663
548
421
315
292
192
616
905
1,019
986
Total Equity
2,208
2,259
2,455
2,689
3,138
3,641
4,716
5,542
5,915
7,727
8,388
Reserve & Surplus
2,183
2,234
2,430
2,663
3,097
3,590
4,676
5,440
5,817
6,307
6,923
Share Capital
25
25
25
25
25
25
25
25
25
25
25

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Net Cash Flow
29
29
-26
75
153
-76
264
432
588
-823
169
Investing Activities
-689
-218
-149
-135
-165
-509
-521
-851
-725
-1,215
-870
Operating Activities
468
709
282
341
501
570
1,090
856
806
945
1,321
Financing Activities
251
-462
-159
-130
-183
-137
-306
427
507
-553
-283

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Promoter
46.29 %
46.29 %
46.29 %
46.29 %
46.29 %
46.29 %
46.29 %
46.29 %
46.29 %
46.29 %
46.29 %
46.29 %
46.30 %
46.30 %
46.30 %
44.72 %
44.72 %
44.72 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.02 %
0.02 %
0.02 %
0.00 %
9.86 %
0.00 %
10.51 %
10.85 %
10.83 %
11.07 %
10.76 %
10.67 %
DIIs
24.49 %
24.86 %
25.00 %
29.73 %
32.41 %
33.31 %
33.29 %
34.03 %
33.55 %
35.19 %
35.05 %
33.79 %
34.37 %
33.78 %
34.23 %
35.68 %
36.06 %
36.20 %
Government
0.28 %
0.22 %
0.22 %
0.24 %
0.24 %
0.24 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
8.74 %
8.25 %
7.61 %
7.75 %
7.79 %
7.50 %
7.44 %
7.41 %
7.26 %
6.98 %
7.14 %
7.12 %
7.13 %
7.27 %
6.93 %
6.88 %
6.81 %
6.82 %
Others
20.20 %
20.39 %
20.89 %
15.99 %
13.27 %
12.66 %
12.97 %
12.26 %
12.89 %
11.54 %
1.67 %
12.80 %
1.69 %
1.79 %
1.71 %
1.65 %
1.65 %
1.59 %
No of Share Holders
1,00,626
1,05,428
95,239
1,06,779
1,15,335
1,10,818
1,11,043
1,08,177
1,10,296
99,889
95,930
82,809
81,165
84,753
82,975
90,189
88,306
85,582

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 0.00 1 1 3 5 8 4 4 4 4
Dividend Yield (%) 0.00 0.31 0.2 0.43 0.53 0.75 0.51 0.32 0.27 0.26

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
11 Aug 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
11 Aug 2025 1,444.40 1,540.80
05 Aug 2025 DIVIDEND Dividend
₹ 2.00 /share
05 Aug 2025 1,495.70 1,540.80
29 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
29 May 2025 1,404.20 1,495.70
13 Feb 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
13 Feb 2025 1,515.65 1,420.40
27 Nov 2024 DIVIDEND Dividend
₹ 2.00 /share
27 Nov 2024 1,504.85 1,564.90
14 Nov 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
14 Nov 2024 1,564.70 1,504.85
13 Aug 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
13 Aug 2024 1,218.00 1,381.60
07 Aug 2024 DIVIDEND Dividend
₹ 2.00 /share
06 Aug 2024 1,319.35 1,320.95
22 Nov 2023 DIVIDEND Dividend
₹ 2.00 /share
22 Nov 2023 1,046.40 1,074.90
23 Nov 2022 DIVIDEND Dividend
₹ 4.00 /share
22 Nov 2022 889.60 863.85
23 Nov 2021 DIVIDEND Dividend
₹ 8.00 /share
22 Nov 2021 1,110.28 1,015.88

Announcements

Board Meeting Intimation for Standalone And Consolidated Results For Q1FY261 day ago
Intimation To ShareholderS Whose E-Mail Addresses Are Not Registered With The Company/Depository Participants/Registrar And Share Transfer Agent7 days ago
Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 14, 2025
Record Date For Members Entitlement Of Final DividendJul 11, 2025
75Th Annual General Meeting Of The Company To Be Held On Monday 11Th August 2025 At 3.30 P.M.Jul 11, 2025
Business Responsibility and Sustainability Reporting (BRSR)Jul 11, 2025
Reg. 34 (1) Annual Report.Jul 11, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 10, 2025
Announcement under Regulation 30 (LODR)-Credit RatingJul 07, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 03, 2025
Order Received Under Central Goods And Service Tax Act 2017Jun 26, 2025
Closure of Trading WindowJun 24, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementJun 16, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 16, 2025
Change In The Name Of Statutory Audit FirmJun 16, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJun 05, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptJun 02, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 30, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 30, 2025
Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 29, 2025
Announcement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of AssociationMay 29, 2025
Announcement under Regulation 30 (LODR)-Dividend UpdatesMay 29, 2025
Standalone And Consolidated Audited Financial Results For Q4FY25May 29, 2025
Board Meeting Outcome for Standalone And Consolidated Audited Financial Results For Q4FY25May 29, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 23, 2025
Board Meeting Intimation for Standalone & Consolidated Audited Financial Results For The 4Th Quarter And FY25 And Recommendation Of Final Dividend For FY 24-25May 14, 2025
General Updates - Unichem Laboratories Ltd. IrelandMay 02, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 07, 2025
Slump Sale Of Manufacturing Unit And AcquisitionMar 28, 2025
Announcement under Regulation 30 (LODR)-AcquisitionMar 28, 2025
Board Meeting Outcome for Outcome Of Board MeetingMar 28, 2025
Closure of Trading WindowMar 26, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementMar 03, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeFeb 18, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 14, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeFeb 13, 2025
Integrated Filing (Financial)Feb 13, 2025
Standalone And Consolidated Q3FY25 ResultsFeb 13, 2025
Board Meeting Outcome for Standalone And Consolidated Q3FY25 Results & Press ReleaseFeb 13, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 10, 2025
Order Received Under CGST ActFeb 07, 2025
Order Received Under Central Goods And Service Tax Act 2017Feb 05, 2025
Orders Received Under CGST ActJan 29, 2025
Board Meeting Intimation for Standalone And Consolidated Unaudited Financial Results For Q3 And Nine Months Ended 31St December 2024Jan 27, 2025
Order Received From Assistant Commissioner CGST RatlamJan 16, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 08, 2025
Change Of Name Of Registrar And Share Transfer Agent ("RTA") Of The CompanyJan 03, 2025
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Dec 23, 2024
Voluntary Closure Of The Company''s Wholly Owned Subsidiary Ipca Pharmaceuticals Ltd SA De CV, MexicoDec 04, 2024
Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 22, 2024

Technical Indicators

RSI(14)
Neutral
74.65
ATR(14)
Volatile
44.09
STOCH(9,6)
Neutral
74.34
STOCH RSI(14)
Neutral
76.30
MACD(12,26)
Bullish
8.69
ADX(14)
Strong Trend
26.72
UO(9)
Bearish
64.79
ROC(12)
Uptrend But Slowing Down
5.16
WillR(14)
Neutral
-30.69

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
HDFC Mid Cap Fund Direct-Growth
2.80%
618053
-0.11%
-0.21%
Kotak Midcap Fund Direct-Growth
2.90%
538005
-0.13%
-0.30%
Aditya Birla Sun Life Multi-Cap Fund Direct-Growth
0.00%
-395720
-0.89%
-0.91%
Franklin India Multi Cap Fund Direct-Growth
0.00%
-343835
-1.01%
-1.03%
Parag Parikh Flexi Cap Fund Direct-Growth
0.17%
-329538
-0.06%
-0.10%
DSP Aggressive Hybrid Fund Direct-Growth
1.13%
313035
0.34%
0.34%
Kotak Multicap Fund Direct - Growth
0.00%
-265469
-0.21%
-0.22%
Baroda BNP Paribas Multi Cap Fund Direct-Growth
0.00%
-249236
-1.25%
-1.46%
Nippon India Vision Large & Mid Cap Direct-Growth
1.68%
-190000
-0.59%
-0.62%
DSP Top 100 Equity Direct Plan-Growth
1.04%
171997
0.33%
0.29%
JM Midcap Fund Direct - Growth
0.96%
-122186
-1.30%
-0.93%
Mirae Asset Healthcare Fund Direct - Growth
2.97%
109060
0.40%
0.75%
Union Flexi Cap Fund Direct-Growth
0.00%
-100000
-0.62%
-0.63%
HDFC Pharma And Healthcare Fund Direct - Growth
4.47%
96495
0.48%
0.99%
DSP Equity Savings Fund Direct-Growth
0.63%
86615
0.36%
0.34%
WhiteOak Capital Pharma and Healthcare Fund Direct - Growth
0.00%
-58628
-2.52%
-2.82%
Edelweiss Nifty Midcap150 Momentum 50 Index Fund Direct - Growth
0.62%
-41854
-0.69%
-0.74%
Union Multi Asset Allocation Fund Direct-Growth
0.00%
-40900
-0.74%
-0.72%
Tata Nifty Midcap 150 Momentum 50 Index Fund Direct - Growth
0.62%
-40736
-0.69%
-0.74%
Union Balanced Advantage Fund Direct - Growth
0.00%
-34500
-0.36%
-0.35%
Union ELSS Tax Saver Fund Direct-Growth
0.37%
-30000
-0.49%
-0.64%
Parag Parikh ELSS Tax Saver Fund Direct - Growth
0.09%
-18646
-0.06%
-0.20%
Baroda BNP Paribas Manufacturing Fund Direct - Growth
1.13%
-18000
-0.24%
-0.38%
Bank of India Multi Cap Fund Direct-Growth
0.00%
-14458
-0.24%
-0.25%
Kotak Nifty Midcap 150 Momentum 50 Index Fund Direct-Growth
0.62%
-8889
-0.68%
-0.74%

About IPCA Laboratories

Ipca Laboratories Limited is an Indian integrated pharmaceutical company that manufactures and markets over 350 formulations and 80 active pharmaceutical ingredients (APIs) across various therapeutic segments. The company operates 18 manufacturing units in India and sells its products in over 100 countries worldwide. Ipca specializes in producing APIs such as Atenolol, Chloroquine Phosphate, Furosemide, and Pyrantel Salts. The company's facilities are approved by major drug regulatory authorities including the US FDA, UK MHRA, and others. Ipca has expanded through acquisitions and joint ventures, and has subsidiaries in various countries. The company focuses on research and development, and has recently acquired stakes in other pharmaceutical companies to strengthen its market position.
Chairperson NamePremchand Godha